21 stories
CagriSema is Novo Nordisk's fixed-combination cagrilintide + semaglutide obesity drug — the company's bid to push the GLP-1 efficacy ceiling higher by adding amylin biology on top of the GLP-1 backbone.
The REDEFINE-1 and REDEFINE-2 Phase 3 trials read out across 2025 and 2026. The February 23, 2026 head-to-head readout against tirzepatide was the inflection point: 23% mean weight loss on CagriSema 2.4/2.4 mg vs 25.5% on tirzepatide 15 mg over 84 weeks, missing the non-inferiority primary endpoint and dropping NVO 15% intraday. Novo's Q1 2026 disclosures (May 6) confirmed a higher-dose CagriSema Phase 3 trial will start in H2 2026, but also disclosed that the company has discontinued the single-chamber co-formulation device project 'due to portfolio considerations' — the dual-chamber injectable system continues, the original FDA filing has been submitted, and a decision is expected late 2026. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg and the Wegovy pill.
Stories here cover the REDEFINE readouts, the regulatory path, and the broader amylin-add-on field. See #cagrilintide for the amylin component and #amylin for class context.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.